The research, led by Iwan Paolucci and colleagues at The University of Texas MD Anderson Cancer Center, tackled a deceptively simple question: how much do the errors built into ablation confirmation software distort the margins we think we are measuring? The concept of an A0 ablation—analogous to the R0 resection in surgery—demands complete tumor coverage with a pre-specified margin, conventionally at least 5 millimeters, and a correspondingly low risk of local tumor progression. But because the tumor is destroyed in situ, the true margin can never be measured histologically. Instead, clinicians rely on an imaging-based surrogate: they co-register pre-ablation and post-ablation scans, contour the tumor and the ablation zone, and compute the shortest three-dimensional distance between them. Every step of that pipeline introduces error, and until now there has been no systematic way to quantify how those errors propagate into the margin threshold that should actually be required.

The team built a mathematical and computational framework that models the entire measurement chain. They identified five key sources of inaccuracy from the literature—image resolution, segmentation error, registration error, tissue deformation, and image artifacts—and folded the last two into related parameters. Segmentation error, the mismatch between a drawn contour and the true boundary of the tumor or ablation zone, was modeled as random noise added to the contours, with tumor and ablation errors treated as independent. Registration error, the misalignment introduced when the two scans are aligned, was modeled as a shift of the ablation zone with a normally distributed magnitude and a random direction along the X, Y, or Z axis. Slice thickness, which ranges from 1 to 5 millimeters in published ablation confirmation studies, was simulated by resampling the synthetic images at different resolutions in the cranio-caudal direction, since in-plane resolution is typically already below 1 millimeter.

Crucially, the researchers also incorporated two biological effects that no imaging system can capture. The first is tissue shrinkage: microwave ablation causes radial contraction of tissue, with ex vivo experiments in bovine liver reporting contraction of up to 40 percent, an upper bound likely inflated by the absence of blood perfusion. Shrinkage within the ablation zone can make the measured margin appear larger than it truly is, and the exact contraction for any individual tumor cannot be observed during the procedure. The second effect is the presence of microscopic satellite lesions—tiny tumor deposits adjacent to the main lesion that fall below the roughly 1-millimeter spatial resolution of cross-sectional imaging. The model assumed these satellites are directly adjacent to the tumor, with sizes uniformly distributed between 0.5 and 2.5 millimeters, and with their presence governed by a binomial probability. Both effects bias the observed margin upward, meaning the measured number can flatter a treatment that has actually fallen short.

The scale of the simulation was enormous: 10,000 individual simulations for each of 1,500 parameter permutations, totaling 15 million synthetic ablation scenarios. In each run, the framework sampled a tumor size and margin, generated synthetic images of the tumor and ablation zone, applied tissue shrinkage and satellite lesions, measured the true margin, then applied registration error, segmentation noise, and slice-thickness resampling before measuring the observed margin. For each parameter combination, a logistic regression was fitted across observed margins ranging from minus 5 to plus 10 millimeters, and the A0 threshold was defined as the observed margin at which the probability of true complete microscopic tumor coverage reached at least 99 percent. The entire framework was implemented in Python and packaged into a freely available web application, allowing clinicians to enter the technical specifications of their own ablation confirmation software and obtain a software-specific A0 threshold.

The results carry a clear hierarchy of blame. Segmentation error emerged as the single most influential factor: with segmentation errors of 1, 3, and 5 millimeters, the required A0 thresholds rose to 3.4, 5.2, and 8.4 millimeters respectively. Registration error followed closely, with thresholds of 3.4, 4.9, and 7.0 millimeters for registration errors of 1, 3, and 5 millimeters. Slice thickness, by contrast, had a negligible effect, shifting the threshold by at most half a millimeter across the 1-to-5-millimeter range—a difference the authors attribute to simulation noise, since it falls below the resolution of the model itself. Among the biological effects, microscopic satellite lesions proved potent: the threshold climbed from 3.4 millimeters with no satellites to 5.8, 7.4, 7.9, and 7.7 millimeters as the probability of satellite presence rose from 25 to 100 percent. Tissue shrinkage worked in the opposite direction, lowering the required threshold from 3.4 millimeters with no shrinkage to 2.8, 2.2, and 1.8 millimeters at 10, 20, and 30 percent contraction.

The practical verdict concerns the sacred 5-millimeter rule. When both segmentation and registration errors were held at or below 3 millimeters, the simulated A0 threshold stayed at or below 5 millimeters, meaning the conventional criterion reliably guaranteed complete tumor coverage in at least 99 percent of cases. But once either error exceeded 3 millimeters, the required threshold climbed above 5 millimeters, and the standard criterion became unreliable—clinicians could believe they had achieved an adequate margin while microscopic disease survived. The study also exposed a subtle bias in the clinical literature: many retrospective studies exclude cases with visually judged registration errors above 3 millimeters before determining optimal margin thresholds. The simulations showed that this exclusion practice systematically lowers the apparent A0 threshold, and that the discrepancy grows as true registration error increases. The authors argue that studies must therefore disclose how many cases were excluded and why.

Why does this matter beyond the statistics? The minimum ablative margin has repeatedly been shown to be the most important predictor of local tumor progression after ablation, and a recent systematic review reinforced 5 millimeters as a minimum requirement while suggesting 10 millimeters as optimal. Yet the field suffers from high heterogeneity, likely driven by differences in measurement methodology and accuracy. Clinical studies capable of validating an A0 threshold for each software package are impractical: the packages evolve rapidly, and capturing the full variation in tumor sizes, margins, and errors would require sample sizes exceeding a thousand patients per comparison. Worse, the biological confounders are fundamentally unmeasurable in patients—microscopic satellites are known only probabilistically from histological studies, and tissue shrinkage only from ex vivo experiments. For rare tumor types particularly prone to satellites, such as intrahepatic cholangiocarcinoma, the necessary sample sizes are simply unattainable. In silico methods like this framework offer the only realistic route to technical validation before clinical deployment.

The authors are candid about the limitations of their approach. Tumors and ablation zones were modeled as spheres and ellipsoids, simplifications of irregular real-world anatomy. Interactions between error sources were ignored, even though a biomechanical deformable registration algorithm, for example, would likely perform worse when fed inaccurate segmentations, and intensity-based registration might suffer from the lower signal-to-noise ratio of thin-slice images. Errors were assumed to follow zero-mean normal distributions, implying no systematic bias—an assumption that may not hold for every commercial package. Registration types, whether rigid or deformable, were not distinguished because their behavior is heavily implementation-dependent. Even so, the study delivers a concrete benchmark: ablation confirmation software should achieve registration and segmentation errors of 3 millimeters or less before its 5-millimeter margin readout can be trusted. For a field increasingly reliant on artificial intelligence-driven contouring and automated margin assessment, that number is now the bar every developer, regulator, and interventional radiologist should be measuring against.

Subject of Research: Effects of measurement errors on minimum ablative margin thresholds in thermal ablation of liver tumors

Article Title: The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study

Article References: Paolucci, I., Albuquerque, J., Siddiqi, N. S., Jones, A. K., Brock, K. K., & Odisio, B. C. (2026). The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study. CVIR Oncology, 2(1), Article 1. https://doi.org/10.1007/s44343-025-00029-9

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00029-9

Keywords: thermal ablation, liver tumors, minimum ablative margin, ablation confirmation software, segmentation error, registration error, simulation study, microwave ablation, colorectal liver metastases, hepatocellular carcinoma, image guidance, A0 margin

The central idea behind the study is neuromodulation, the deliberate adjustment of nerve activity to change the function of an organ. For the heart, the relevant nerves belong to the autonomic nervous system, the network that operates largely outside conscious control. Sympathetic branches act like an accelerator, speeding the heart when the body demands more oxygen, while parasympathetic branches act as a brake, slowing it during rest and recovery. Clinicians have long known that adjusting this balance can treat rhythm disorders, but the tools available to do so have been crude, invasive, or both. Focused ultrasound offers a way to deliver energy to a precisely defined volume of tissue deep inside the body, stimulating or suppressing neural structures without any incision.

Ultrasound neuromodulation has attracted growing interest over the past decade because sound waves interact with tissue in ways that electrodes cannot. An ultrasound transducer can focus acoustic energy at a target millimeters across, several centimeters beneath the skin, while leaving intervening tissue essentially untouched. The mechanical and thermal effects of the focused beam can alter the excitability of nerve fibers, changing how likely they are to fire action potentials. Depending on the acoustic parameters chosen, the same technology can excite or inhibit neural activity, giving researchers a reversible dial for nervous system function rather than a simple on-off switch.

What distinguishes the new work is the emphasis on image guidance. Delivering energy to the region around the heart is technically demanding because the target moves constantly with each heartbeat and shifts with every breath. The researchers integrated their ultrasound system with imaging that allowed them to track and compensate for this motion, keeping the acoustic focus locked on the intended neural target as the body moved. This kind of closed-loop control is widely regarded as essential if ultrasound neuromodulation is ever to leave the laboratory, because even small targeting errors could disperse the acoustic energy to unintended structures or miss the nerve tissue altogether.

The reported outcome is that this image-guided stimulation could regulate heart rate. By directing focused ultrasound at cardiac neural targets, the team demonstrated that the technique could influence the pace of the heartbeat in a controlled fashion, adjusting the balance between the nerves that accelerate the heart and those that slow it. Regulation, rather than simple stimulation, is the crucial claim. A clinically useful therapy would need to raise or lower heart rate on demand, or damp pathological overactivity, and the study presents its approach as capable of that kind of bidirectional control.

The technical machinery required for this achievement is considerable. High-intensity focused ultrasound systems of the kind used for ablating tumors deliver enough energy to destroy tissue, but neuromodulation typically operates at far lower intensities, below thresholds that would cause lasting damage. The acoustic parameters, including frequency, pulse duration, and repetition rate, determine whether the beam primarily excites nerve fibers, suppresses them, or produces transient heating that changes their behavior. Finding parameter sets that reliably modulate cardiac nerves without harming the surrounding myocardium is one of the field’s central challenges, and the published work contributes data toward that goal.

Why does this matter for medicine? Disturbances of heart rate and rhythm are among the most common and lethal problems in clinical cardiology. Abnormally fast rhythms, abnormally slow rhythms, and chaotic fibrillation all arise from malfunctions in the heart’s electrical control system, and the autonomic nerves that supply the heart are deeply implicated in many of these conditions. Catheter ablation, in which a physician threads wires into the heart and burns small areas of tissue, is effective for some disorders but is invasive and carries procedural risk. Drugs can modulate autonomic tone but act throughout the body, producing side effects far from the heart. A noninvasive, focal, and reversible method for adjusting cardiac nerve activity would fill a genuine gap in the therapeutic arsenal.

The study also speaks to a broader trend in bioelectronic medicine, a field built on the idea that many diseases can be treated by adjusting the electrical signals carried by nerves rather than by delivering chemicals. Researchers have implanted electrodes on the vagus nerve to treat epilepsy and inflammatory conditions, and others have explored stimulation of the carotid sinus and spinal cord for cardiovascular indications. Ultrasound offers these same possibilities from outside the body, which would eliminate implantation surgery and infection risk. The heart, with its well-mapped autonomic innervation and its easily monitored output, is a natural proving ground for the concept, because heart rate itself provides an immediate, continuous readout of whether the neuromodulation is working.

As with any early-stage study, important questions remain before patients could benefit. The durability of the effect, the precise neural structures targeted, the safety margins for repeated sessions, and the translation of results across species are all matters that will require further investigation. The team’s own account presents the work as a demonstration of feasibility: that image guidance can keep a focused ultrasound beam on a moving cardiac target, and that the resulting neuromodulation is sufficient to regulate heart rate. Scaling from demonstration to therapy will demand larger and longer studies, refinement of the targeting algorithms, and careful assessment of any off-target effects on neighboring tissue.

Nevertheless, the publication marks a noteworthy step for a technology that many researchers hope will reshape how medicine interacts with the nervous system. The combination of focused ultrasound with real-time imaging transforms neuromodulation from a procedure requiring precision hardware implanted inside the body into something closer to an examination: the patient lies still, the imaging system tracks the target, and the acoustic beam delivers its influence without a single incision. If subsequent studies confirm and extend these results, the day may come when clinicians tune the heart’s rhythm the way this study did, with sound alone, guided by images, and reversed the moment the therapy ends.

The physics underlying this approach rewards a closer look, because it explains both the promise and the difficulty of the method. Ultrasound waves at the megahertz frequencies typically used for neuromodulation travel through soft tissue at roughly fifteen hundred meters per second and can be steered by phasing the emissions of hundreds of individual elements on a transducer array. Each element fires with a slightly different delay, so that the wavefronts arrive simultaneously at a chosen point, constructive interference concentrates the acoustic pressure there, and tissue elsewhere receives comparatively little energy. This electronic steering means the focus can be repositioned in milliseconds purely by changing the timing signals, a property that pairs naturally with the fast feedback demanded by a beating heart.

The choice of neural target is equally consequential. The heart’s autonomic control is organized around ganglionated plexi, clusters of neurons embedded in the epicardial fat pads near the pulmonary veins, the superior vena cava, and the atria. These microganglia act as local integration centers, relaying and processing signals from the vagus nerve and the sympathetic chain before they reach the cardiac conduction system. Cardiac surgeons and electrophysiologists have known for decades that disturbing these clusters alters atrial rhythm tendencies, which is precisely why they represent attractive targets for noninvasive modulation. Delivering acoustic energy to such small structures, however, requires submillimeter accuracy sustained over many cardiac cycles.

Motion compensation of this kind borrows heavily from techniques developed in radiation oncology, where tumor-tracking linear accelerators adjust beam delivery to a patient’s respiratory cycle. The cardiac problem is harder still, because the heart moves faster than the lungs and exhibits beat-to-beat variability. A successful tracking system must therefore anticipate where the target will be when each acoustic pulse arrives, rather than simply following its past position, and any latency in the imaging chain must be accounted for in the control algorithm.

Safety considerations extend beyond the avoidance of thermal injury. Regulatory frameworks for medical ultrasound, built around indices that estimate heating and the potential for cavitation, will need to be interpreted carefully for a therapy whose intended effect is functional rather than destructive. Repeated exposure of the same neural tissue raises questions about cumulative changes in nerve excitability, and the possibility that acoustic energy scattered by ribs or lung tissue could stimulate unintended structures deserves systematic study. The chest wall itself presents an acoustic obstacle, since bone reflects and absorbs ultrasound strongly, so coupling of the beam through an intercostal window is a practical constraint on positioning.

The experimental logic of using heart rate as an endpoint also deserves emphasis. Unlike modulation of deeper brain circuits, where effects must be inferred indirectly, cardiac neuromodulation produces a continuous, quantitative, beat-by-beat readout that can be captured with noninvasive electrocardiography. This tight feedback loop makes the heart an ideal model system for validating the principles of image-guided acoustic neuromodulation generally, and lessons learned here may well inform applications to the peripheral and central nervous system, where comparable targeting and monitoring challenges await solutions.

Subject of Research: Noninvasive image-guided focused ultrasound neuromodulation of cardiac autonomic nerves to regulate heart rate

Article Title: Image-guided cardiac focused ultrasound neuromodulation regulates heart rate

Article References: Piao, X., Wei, Y., Yao, X., Xu, Z., Pan, J.-J., Hu, P., & Cheng, B. (2026). Image-guided cardiac focused ultrasound neuromodulation regulates heart rate. Communications Engineering. https://doi.org/10.1038/s44172-026-00774-6

Image Credits: AI Generated

DOI: 10.1038/s44172-026-00774-6

Keywords: focused ultrasound, neuromodulation, heart rate, autonomic nervous system, image guidance, cardiology, bioelectronic medicine, ultrasound therapy, cardiac nerves, noninvasive stimulation, Image-guided, cardiac